Compare GSK plc (GSK) vs ProShares Ultra QQQ ETF (QLD) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

QLD, the ProShares Ultra QQQ ETF, is currently trading at $88.73, down 3.69% on the day, reflecting a bearish technical signal. The leveraged ETF, which aims for 2x the daily return of the Nasdaq-100, lacks traditional fundamental ratios like P/E or P/S as it is a fund. Recent news highlights its long-term compounding power and ongoing discussions about its role in tactical portfolios and retirement strategies, though comparisons with higher-leverage alternatives like TQQQ note its relatively lower historical maximum drawdown.

The outlook for QLD is directly tied to the performance of the tech-heavy Nasdaq-100. While offering amplified daily returns, it carries significant risks from market volatility and compounding effects over longer periods. The primary opportunity is tactical participation in strong tech rallies, but the risk of severe drawdowns during downturns necessitates a cautious, short-term trading approach rather than a long-term buy-and-hold strategy.